AstraZeneca presents new data at ESC Congress 2020

29 August - 1 September

At AstraZeneca, we are committed to advancing science and bringing life-changing therapies to those who need them most. Our presence at ESC Congress 2020 – The Digital Experience will include unveiling new data on Farxiga (dapagliflozin), Lokelma (sodium zirconium cyclosilicate) and Brilinta (ticagrelor).

Data will showcase our efforts to address shared risk factors and unmet needs across the full continuum of cardiovascular, renal and metabolic (CVRM) care – from early prevention, protection and treatment, to slowing disease progression and managing serious complications.

We also look forward to sharing detailed results from the DAPA-CKD trial, following on from the high-level results announced in July.

This year’s virtual event is available at no charge, but pre-registration is required.

Our Abstracts

Chronic kidney disease

Highly anticipated detailed results from the DAPA-CKD trial, in which Farxiga significantly reduced the worsening of renal function or cardiovascular (CV) or renal death in patients with and without type-2 diabetes (T2D).


Heart failure

New sub-analyses from the Farxiga DAPA-HF trial, insights on the burden of hyperkalaemia in heart failure (HF) and early science research on epigenetics in HF.


Cardiovascular disease

Insights into Brilinta’s effects on saphenous vein graft patency, its benefits in patient subgroups from the THEMIS trial, plus real-world evidence on outcomes for THEMIS-like patients with type-2 diabetes and coronary artery disease without prior myocardial infarction or stroke.

Hiddo Lambers Heerspink

Hiddo Lambers Heerspink University Medical Center Groningen

Professor Heerspink is co-chair of the DAPA-CKD trial and its executive committee. He is a Clinical Pharmacologist at the University Medical Center Groningen. His main research interests include optimising treatment strategies and finding new therapeutic approaches to halt the progression of renal and cardiovascular disease. He is presenting, “DAPA-CKD: Dapagliflozin in patients with CKD,” a live oral presentation.

David Wheeler

David Wheeler University College London

Professor Wheeler is co-chair of the DAPA-CKD trial and its executive committee. He is Professor of Kidney Medicine at University College London, Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust, and Honorary Professorial Fellow of the George Institute for Global Health. His research interest is in the complications of CKD, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure.

Abstract list

All ESC Congress 2020 abstracts are available via the Scientific Programme & Planner.

Farxiga (dapagliflozin) 

·         DAPA-CKD: Dapagliflozin in patients with chronic kidney disease – Heerspink, H. (Hot Line, Live Prime Time Discussion, Q&A)

·         Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: A secondary analysis DAPA-HF – Kristensen, S.L. (Rapid fire abstract) 

·         Efficacy and safety of dapagliflozin according to baseline blood Pressure - Observations From DECLARE-TIMI 58 Trial – Furtado, R. (Oral presentation) 

·         Natriuretic effect of 2 weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function: Results of the DAPASALT trial – Scholtes, R.A. (Oral rapid fire abstract) 

·         The effect of dapagliflozin in patients with HFrEF and COPD: A post-hoc analysis of DAPA-HF – Dewan, P. (ePoster presentation)

·         The effect of dapagliflozin across the spectrum of baseline risk: A post-hoc analysis of DAPA-HF – Docherty, K.F. (ePoster presentation)


Lokelma (sodium zirconium cyclosilicate) 

·         The relationship between duration of heart failure, serum potassium concentration and adverse clinical outcomes – McEwan, P. (Oral presentation) 

·         Estimating the burden of hyperkalaemia in the UK in high-risk patient populations – McEwan, P. (ePoster presentation) 

·         Assessing the relationship between serum potassium variability and the risk of hyperkalaemia and adverse clinical outcomes – McEwan, P. (ePoster presentation) 


Brilinta (ticagrelor) 

·         Cardiovascular and limb event risk and the benefit of ticagrelor in Patients with and without peripheral artery disease: Insights from the THEMIS Trial – Bonaca, M.P. (Oral presentation)

·         The effect of one-year postoperative ticagrelor in addition to aspirin on saphenous vein graft patency in patients undergoing CABG – a randomized, multi-center, double-blind, placebo-controlled trial – Willemsen, L.M. (Oral presentation) 

·         Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease with a history of PCI: An economic evaluation of THEMIS-PCI using a Swedish healthcare perspective – Steg, P.G. (ePoster presentation) 

·         Prevalence of type 2 diabetes with stable coronary artery disease but without prior myocardial infarction or stroke and THEMIS-like patients from the SNDS French nationwide claims database – Blin, P. (ePoster presentation) 

·         Real world risk of major outcomes for type 2 diabetes with stable coronary artery disease without prior MI or stroke and THEMIS-like patients using the SNDS French nationwide claims database – Blin, P. (ePoster presentation) 

·         Administration of a soluble ADPase, AZD3366, on top of ticagrelor confers additional cardioprotective benefits to that of ticagrelor alone – Vilahur, G. (ePoster presentation) 

Orodispersible ticagrelor use in acute coronary syndrome patients: the Ticagrelor Administered as Standard Tablet or orodispersible formulation (TASTER) Study – Parodi, G. (ePoster presentation


1. World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 2020 Aug 10]. Available from: URL:

2. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390(10100):1211–59.

3. National Health Service. Symptoms: Chronic kidney disease; 2016 [cited 2020 Aug 10]. Available from: URL:

4. International Diabetes Federation. IDF Diabetes Atlas - 9th Edition. 9th ed.; 2019 [cited 2020 Aug 10]. Available from: URL:

5. Hayes A et al. Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. Value Health 2016; 19(1):36–41.

Veeva ID: Z4-25830
Date of Preparation: August 2020